Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Editor.
JAMA Ophthalmol. 2018 Jun 1;136(6):658-664. doi: 10.1001/jamaophthalmol.2018.1272.
While symptomatic vitreomacular interface abnormalities (VIAs) are common, assessment of vision preference values and treatment preferences of these may guide treatment recommendations by physicians and influence third-party payers.
To determine preference values that individuals with VIA assign to their visual state and preferences of potential treatments.
DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional one-time questionnaire study conducted between December 2015 and January 2017, 213 patients from tertiary care referral centers in Thailand, the United Kingdom, and the United States were studied. Patients with symptomatic VIA diagnosed within 1 year of data collection, visual acuity less than 20/20 OU, and symptoms ascribed to VIAs were included. Data were analyzed from January 2017 to November 2017.
The primary end points were overall mean preference value that individuals with VIA assigned to their visual state and patients' preferences for potential treatments. Preference values were graded on a scale from 0 to 1, with 0 indicating death and 1 indicating perfect health with perfect vision.
Of the 213 included patients, 139 (65.3%) were women, and the mean (SD) age was 65.6 (7.7) years. Diagnoses included epiretinal membrane (n = 100 [46.9%]), macular hole (n = 99 [46.5%]), and vitreomacular traction (n = 14 [6.6%]). The mean (SD) vision preference value was 0.76 (0.15), without differences identified among the 3 VIA types. More participants were enthusiastic about vitrectomy (150 [71.1%]) compared with intravitreal injection (120 [56.9%]) (difference, 14.2%; 95% CI, 5.16-23.3; P = .002). Adjusted analyses showed enthusiasm for vitrectomy was associated with fellow eye visual acuity (odds ratio, 10.99; 95% CI, 2.01-59.97; P = .006) and better-seeing eye visual acuity (odds ratio, 0.03; 95% CI, 0.001-0.66; P = .03). Overall enthusiasm for treatment was associated with fellow eye visual acuity (odds ratio, 7.22; 95% CI, 1.29-40.40; P = .02). Overall, most participants (171 [81.0%]) were enthusiastic about surgery, injection, or both.
Study participants reported similar preference values among 3 types of VIAs. The data suggest that most patients with these conditions would be enthusiastic about undergoing vitrectomy or an injection to treat it, likely because of the condition's effect on visual functioning, although there may be a slight preference for vitrectomy at this time.
虽然有症状的玻璃体黄斑界面异常(VIA)很常见,但评估这些异常的视力偏好值和治疗偏好值可能有助于医生提出治疗建议,并影响第三方支付者。
确定 VIA 患者对其视觉状态的偏好值以及对潜在治疗方法的偏好。
设计、地点和参与者:本横断面一次性问卷调查研究于 2015 年 12 月至 2017 年 1 月在泰国、英国和美国的三级医疗转诊中心进行,共纳入 213 例患者。纳入标准为:在数据收集后 1 年内诊断为有症状的 VIA,视力低于 20/20 OU,且症状归因于 VIA。数据分析于 2017 年 1 月至 2017 年 11 月进行。
主要终点为 VIA 患者对其视觉状态的总体平均偏好值和患者对潜在治疗方法的偏好。偏好值评分范围为 0 至 1,0 表示死亡,1 表示完美健康和完美视力。
213 例纳入患者中,139 例(65.3%)为女性,平均(SD)年龄为 65.6(7.7)岁。诊断包括视网膜前膜(n=100[46.9%])、黄斑裂孔(n=99[46.5%])和玻璃体黄斑牵引(n=14[6.6%])。平均(SD)视力偏好值为 0.76(0.15),3 种 VIA 类型之间无差异。与玻璃体内注射(120 例[56.9%])相比,更多患者对玻璃体切除术(150 例[71.1%])更感兴趣(差异,14.2%;95%CI,5.16-23.3;P=.002)。调整分析显示,对玻璃体切除术的兴趣与对侧眼视力(比值比,10.99;95%CI,2.01-59.97;P=.006)和较好眼视力(比值比,0.03;95%CI,0.001-0.66;P=.03)有关。总体上对治疗的兴趣与对侧眼视力(比值比,7.22;95%CI,1.29-40.40;P=.02)有关。总体而言,大多数参与者(171 例[81.0%])对手术、注射或两者都感兴趣。
研究参与者报告了 3 种 VIA 类型之间相似的偏好值。数据表明,这些情况下的大多数患者都热衷于接受玻璃体切除术或注射治疗,这可能是因为这种情况对视觉功能的影响,尽管目前可能对玻璃体切除术略有偏好。